Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORF-057 in Moderately to Severely Active Ulcerative Colitis
NCT05611671Phase 2Completed
- Sponsor
- Morphic Therapeutic
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of LY4268989 in ulcerative colitis (UC) (4 arms), sponsored by Morphic Therapeutic. Primary endpoint: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) at 12 weeks. Started Nov 2022; status: completed.
02
Drugs
LY4268989
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05611671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611671.